Increased circulating visfatin is associated with progression of kidney disease in non-diabetic hypertensive patients

Chien Yi Hsu, Po Hsun Huang, Tz Heng Chen, Chia Hung Chiang, Hsin Bang Leu, Chin Chou Huang, Jaw Wen Chen, Shing Jong Lin

Research output: Contribution to journalArticlepeer-review

12 Citations (Scopus)


BACKGROUD: Declining renal function is an independent risk factor for all-cause mortality in cardiovascular disease. Visfatin has been described as a marker of inflammation and endothelial dysfunction, but whether circulating visfatin levels are predictive to a subsequent decline in renal function remains unclear. METHODS: In total, 200 nondiabetic, non-proteinuric hypertensive outpatients with initial serum creatinine (Scr) ≤1.5 mg/dl were enrolled. Plasma visfatin concentration and endothelial function estimated by brachial artery flow-mediated dilatation (FMD) were determined in the study subjects. The primary endpoints were the occurrence of renal events including doubling of Scr, 25% loss of glomerular filtration rate (GFR) from baseline values, and the occurrence of end-stage renal disease during follow-up. RESULTS: The mean annual rate of GFR decline (ΔGFR/y) was -1.26 ± 2.76 ml/ min/1.73 m2 per year during follow-up (8.6 ± 2.5 years). At baseline, plasma visfatin was negatively correlated with estimated GFR. In longitudinal analysis, the ΔGFR/y was correlated with visfatin, baseline GFR, FMD, systolic blood pressure, and fasting blood glucose (FBG). Multivariate analysis indicated that increased visfatin (r = -0.331, P <0.001), baseline GFR (r = -0.234, P = 0.001), FMD (r = 0.163, P = 0.015), and FBG (r = -0.160, P = 0.015) are independent predictors of ΔEGFR/y. Cox regression model analysis showed that visfatin (hazard ratio (HR), 1.09; 95% confidence interval (CI), 1.05-1.13, P <0.001), FBG (HR, 1.01; 95% CI, 1.00-1.02, P = 0.020), and FMD (HR, 0.87; 95% CI, 0.76-1.00, P = 0.049) were independently associated with the risk of developing future renal events. CONCLUSIONS: Increased circulating visfatin are associated with subsequent decline in renal function in nondiabetic hypertensive patients.

Original languageEnglish
Pages (from-to)528-536
Number of pages9
JournalAmerican Journal of Hypertension
Issue number4
Publication statusPublished - Jan 1 2016
Externally publishedYes


  • Adipokine
  • Blood pressure
  • Chronic kidney disease
  • Endothelial dysfunction
  • Hypertension
  • Visfatin

ASJC Scopus subject areas

  • Internal Medicine


Dive into the research topics of 'Increased circulating visfatin is associated with progression of kidney disease in non-diabetic hypertensive patients'. Together they form a unique fingerprint.

Cite this